Printer Friendly

ANGEION RECEIVES FDA APPROVAL TO BEGIN CLINICAL TRIALS; TO TEST LASER CATHETER FOR NONSURGICAL TREATMENT OF RAPID HEARTBEATS

 MINNEAPOLIS, Dec. 15 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) announced today that its subsidiary, AngeLase, Inc., has received final approval from the U.S. Food and Drug Administration to test its laser catheter ablation system in a nonsurgical procedure to treat rapid heartbeats known as ventricular tachycardia.
 Phase one of the human clinical trials will be conducted by Robert H. Svenson, M.D., at the Carolinas Heart Institute in Charlotte, N.C. Svenson is also principal investigator for AngeLase's current FDA- approved clinical trials which have been testing the laser catheter ablation system in open chest surgeries to treat ventricular tachycardia.
 Angeion's goal is to develop the device nonsurgically as a cure for some patients who suffer from the life-threatening rapid heartbeats which kill approximately 450,000 adults in the United States each year.
 Minneapolis-based Angeion is developing products to treat various types of arrhythmias or irregular heartbeats. In addition to the laser catheter device, Angeion is also developing an implantable defibrillator and external temporary pacemaker.
 -0- 12/15/92
 /CONTACT: Brenda Roth of Angeion, 612-550-9388/
 (ANGN)


CO: Angeion Corporation ST: Minnesota IN: MTC SU: PDT

KH -- MN002 -- 7107 12/15/92 10:38 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 15, 1992
Words:194
Previous Article:CATALINA COMPLETES TURNAROUND YEAR WITH STRONG FOURTH QUARTER
Next Article:FIBRONICS INTERNATIONAL INC. APPOINTS GIL WEISER AS PRESIDENT-CEO
Topics:


Related Articles
ADVANCED INTERVENTIONAL SYSTEMS ADDS NEW CATHETER TO CLINICAL TRIALS WITH EXCIMER LASER SYSTEM
ANGEION PERFORMS FIRST PRE-CLINICAL IMPLANTATION OF ITS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; RECEIVES ALLOWANCE ON TWO IMPORTANT PATENTS
ANGEION UPDATES SHAREHOLDERS AT ANNUAL MEETING
ANGEION INITIATES CLINICAL TRIALS IN UNITED KINGDOM
ANGEION RECEIVES FDA AUTHORIZATION TO CONDUCT CLINICAL TRIALS
ANGEION RECEIVES FDA AUTHORIZATION TO CONDUCT CLINICAL TRIALS
ANGEION ICD IMPLANTED BY ST. JUDE/PACESETTER
Angeion Begins FDA Approved Clinicals of Sentinel 2010 ICD System
Angeion Receives Approval to Market Sentinel 2011 and 2012 ICD Systems in Europe
Angeion Revises Clinical Trial Protocol

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters